Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Depression affects approximately 2.5% of children and 8% of adolescents. Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to provide a systematic evaluation of the safety and efficacy of escitalopram in the treatment of depressed pediatric patients, 12 to 17 years of age. Patients completing the study will be eligible to enter an open-label extension study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Escitalopram | Experimental | Escitalopram 10mg once daily for three weeks, 10-20mg once daily for up to the remaining 5 weeks |
|
| 2 | Placebo Comparator | Placebo once daily for up to 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Escitalopram | Drug | Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score | Change from baseline to week 8 in Children's Depression Rating Scale total score. The scale measures 17 depressive symptoms, of which 3 are rated 1-5 and 14 are rated 1-7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17-113. | Baseline to end of week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Global Impressions - Improvement | Clinical Global Impressions - Improvement score at the end of week 8. The scale rates improvement or worsening of patient mental health relative to baseline on a scale from 1 (very much improved) to 7 (very much worse). | CGI-I score at the end of Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Children's Global Assessment Scale | Change from baseline to week 8 in CGAS score which rates the patient's general level of functioning for the past 14 days on a scale of 1 (most impaired) to 100 (healthiest). | At baseline and end of week 8 |
Inclusion Criteria:
Exclusion Criteria:
Patients who currently meet DSM-IV criteria for:
Patients who are considered a suicide risk (have active suicidal ideation), who have made a suicide attempt, or who have ever been hospitalized because of a suicide attempt.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daniel Ventura, PhD | Forest Research Institute, a subsidiary of Forest Laboratories, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California at Davis, MIND Institute, Health Services | Sacramento | California | 95817 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19465881 | Result | Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):721-729. doi: 10.1097/CHI.0b013e3181a2b304. |
Not provided
Not provided
2 week screening with one-week single-blind placebo. Patients meeting selection criteria at baseline were randomized to once daily escitalopram 10-20mg/day or placebo (1:1).
Recruitment period was from April 1, 2005 through March, 2007 at 40 centers in the US.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Escitalopram | Once daily oral administration of escitalopram tablets - 1 tablet (10mg) for the first three weeks, then 1 tablet (10mg or 20mg) depending on therapeutic response and tolerability. |
| FG001 | Placebo |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo once daily for up to 8 weeks |
|
| UCSD Outpatient Psychiatry Services |
| San Diego |
| California |
| 92103 |
| United States |
| PCSD - Feighner Research | San Diego | California | 92111 | United States |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | United States |
| University of Florida - Child Study Program | Gainesville | Florida | 32610 | United States |
| Clinical Neuroscience Solutions, Inc. | Jacksonville | Florida | 32216 | United States |
| Janus Center for Psychiatric Research | West Palm Beach | Florida | 33407 | United States |
| Kolin Research Group | Winter Park | Florida | 32789 | United States |
| Capstone Clinical Research | Libertyville | Illinois | 60048 | United States |
| Clinco | Terre Haute | Indiana | 47802 | United States |
| Psychiatric Associates | Overland | Kansas | 66211 | United States |
| Pharmasite Research, Inc. | Baltimore | Maryland | 21208 | United States |
| Capitol Clinical Research Associates | Rockville | Maryland | 20852 | United States |
| St. Charles Psychiatric Associates | Saint Charles | Missouri | 63301 | United States |
| Creighton University Medical School, Department of Psychiatry | Omaha | Nebraska | 68131 | United States |
| CNS Research Institute | Clementon | New Jersey | 08021 | United States |
| Pulmonary and Allergy Associates, P. A. | Summit | New Jersey | 07901 | United States |
| North Carolina Neuropsychiatry, PA | Chapel Hill | North Carolina | 27514 | United States |
| University of Cincinnati College of Medicine, Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | United States |
| University Hospitals of Cleveland, Division of Child & Adolescent Psychiatry | Cleveland | Ohio | 44106 | United States |
| IPS Research Company | Oklahoma City | Oklahoma | 73103 | United States |
| University of Pennsylvania, Department of Psychiatry, Mood & Anxiety Disorders Section | Philadelphia | Pennsylvania | 19104 | United States |
| Drexel University College of Medicine, Friends Hospital | Philadelphia | Pennsylvania | 19124 | United States |
| Clinical Neuroscience Solutions | Memphis | Tennessee | 38119 | United States |
| University of Texas Southwestern Medical Center, Center for Pediatric Psychiatry | Dallas | Texas | 75235 | United States |
| University of Texas Medical Branch, Department of Psychiatry & Behavioral Sciences | Galveston | Texas | 77555 | United States |
| Brighton Research Group, LLC | Virginia Beach | Virginia | 23452 | United States |
| Northwest Clinical Research Center | Bellevue | Washington | 98004 | United States |
Once daily oral administration of placebo tablets
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Escitalopram | Once daily oral administration of escitalopram tablets - 1 tablet (10mg) for the first three weeks, then 1 tablet (10mg or 20mg) depending on therapeutic response and tolerability. |
| BG001 | Placebo | Once daily oral administration of placebo tablets |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score | Change from baseline to week 8 in Children's Depression Rating Scale total score. The scale measures 17 depressive symptoms, of which 3 are rated 1-5 and 14 are rated 1-7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17-113. | Efficacy analyses used Intent-To-Treat Population, which consisted of all patients who received at least 1 dose of double-blind study drug & who had at least 1 post-baseline assessment of the CDRS-R. LOCF technique was used to impute missing data. 1 escitalopram pt. did not have a post-baseline CDRS-R total score. | Posted | Apr 2009 | Mean | Standard Error | Change in total score at endpoint | Baseline to end of week 8 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Clinical Global Impressions - Improvement | Clinical Global Impressions - Improvement score at the end of week 8. The scale rates improvement or worsening of patient mental health relative to baseline on a scale from 1 (very much improved) to 7 (very much worse). | The Intent-To-Treat Population was used. The Last Observation Carried Forward (LOCF) technique was used to impute missing data. | Posted | Apr 2009 | Mean | Standard Error | Score on scale | CGI-I score at the end of Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Children's Global Assessment Scale | Change from baseline to week 8 in CGAS score which rates the patient's general level of functioning for the past 14 days on a scale of 1 (most impaired) to 100 (healthiest). | The Intent-To-Treat Population was used. The Last Observation Carried Forward (LOCF) technique was used to impute missing data. | Posted | Apr 2009 | Mean | Standard Error | Change in score | At baseline and end of week 8 |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Escitalopram | Once daily oral administration of escitalopram tablets - 1 tablet (10mg) for the first three weeks, then 1 tablet (10mg or 20mg) depending on therapeutic response and tolerability. | 4 | 155 | 121 | 155 | ||
| EG001 | Placebo | Once daily oral administration of placebo tablets | 2 | 157 | 118 | 157 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Inflicted Injury | General disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Irritability | Psychiatric disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Suicidal Tendency | Psychiatric disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Depression Aggravated | Psychiatric disorders | WHOART v.1998/04 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | Nervous system disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Insomnia | Psychiatric disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Abdominal Pain | Gastrointestinal disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Inflicted Injury | General disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Pharyngitis | Respiratory, thoracic and mediastinal disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Fatigue | General disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Influenza-like Symptoms | General disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Rhinitis | Respiratory, thoracic and mediastinal disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Menstrual Cramps | Reproductive system and breast disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | WHOART v.1998/04 | Non-systematic Assessment |
| |
| Upper Respiratory Tract Infections | Respiratory, thoracic and mediastinal disorders | WHOART v.1998/04 | Non-systematic Assessment |
|
Sponsor can review results communications prior to public release & can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential info. Upon sponsor's request, PI shall delete any proprietary info & shall not include raw data in pub. On sponsor's request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Daniel Ventura, PhD | Forest Research Institute, a subsidiary of Forest Laboratories, Inc. | 201-427-8252 | daniel.ventura@frx.com |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000089983 | Escitalopram |
| ID | Term |
|---|---|
| D011437 | Propylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D009570 | Nitriles |
| D001572 | Benzofurans |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| >=65 years |
|
| Male |
|
Differences are Escitalopram-Placebo |
| No |
| Superiority or Other |
|
|
|
|